According to the FDA prescribing information, these include nausea, vomiting, diarrhea, abdominal pain, and constipation
In this Review, we discuss how this advanced knowledge, aligned with new approaches, can enable effective translation of therapeutic agents from preclinical studies through to clinical benefit for patients with ALS
However, anaesthetists must take into account the theoretical increased risk of aspiration in patients taking GLP-1 agonists, as presented by the aforementioned case reports
Full basal-bolus therapy consists of basal insulin and three daily injections of short-acting insulin at mealtime, while the term basal-plus therapy refers to a regimen that includes a basal insulin injection, with the gradual addition of one to three pre-prandial short-acting insulin doses per day
rarely felt by the child at all
Welcome to another episode of Revolution Health Radio